Immuneering Corp

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Immuneering Corp advances oncology focus with promising preclinical data

Immuneering Corp (IMRX) is making significant strides in oncology with promising preclinical data and a strategic focus on developing cancer treatments with better tolerability.
While facing challenges in addressing resistance and clarifying MEK inhibitor activity, the company's unique approach and strong response profiles position them well for future growth.
Opportunities lie in advancing pipeline assets, optimizing clinical trial outcomes through informatics, and leveraging expertise in relevant cancer types for Phase 2a success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 13.79% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates

First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation

Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will participate in two March investor conferences to share commentary around the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Immuneering Announces Participation in March Investor Conferences

Management to host conference call on Monday, March 6 at 4:30 p.m. ET Management to host conference call on Monday, March 6 at 4:30 p.m. ET

Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activating events, today announced that management will present at Guggenheim's 2023 Oncology Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.

Immuneering To Present at Guggenheim 2023 Oncology Conference

Affimed

BioAtla, Inc

Eiger BioPharmaceuticals

Gracell Biotechnologies

Nkarta, Inc.

Instil Bio

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

7 Cheap But Risky Biotech Stocks

IMM-1-104 being tested in first all-comers RAS clinical trial believed to be conducted to date

Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates

Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter

Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint Blockade

Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced that management will participate in three November investor conferences to share commentary around the Company's pipeline, platform, and business strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific Officer.

Immuneering Announces Participation in November Investor Conferences

Acumen Pharmaceuticals

Akero Therapeutics Inc

FaZe Holdings Inc

Forge Global Holdings Inc

Grove Collaborative Holdings

Novavax

Cassava Sciences Inc

Value Line

Ventyx Biosciences

Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.

These Are the Five Best and Worst Performing Small-cap Stocks in September 2022

CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced the appointment of Leah R. Neufeld to the newly created position of Chief People Officer, effective immediately.

Immuneering Appoints Leah R. Neufeld as Chief People Officer

Applied DNA Sciences

Avenue Therapeutics

HeartBeam

Mind Medicine MindMed

PhaseBio Pharmaceuticals Inc

Shuttle Pharmaceuticals Holdings Inc

Spero Therapeutics

Virios Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced it will present data on its second program IMM-6-415 in a poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 8-12, 2022 in Boston or virtually.

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Immuneering Corporation (IMRX) a New Buy Stock

Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022 Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

The average of price targets set by Wall Street analysts indicates a potential upside of 148% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?

Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.

Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104

CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The IND application supports a Phase 1/2a clinical trial of IMM-1-104, an oral once daily small molecule in development for the treatment of advanced RAS mutant solid tumors. In contrast to the narrow approach of targeting specific mutations such as KRAS-G12C, IMM-1-104 is a third generation MEK inhibitor designed for broad pan-RAS activity as well as activity in other MAPK-activated tumors. Based on preclinical data to date, IMM-1-104 has demonstrated robust single-agent anti-tumor activity across a broad range of in vitro and in vivo tumor models driven by MAPK pathway activation events. This includes animal models of KRAS mutant pancreatic cancer, NRAS mutant melanoma, KRAS mutant colorectal cancer, and KRAS mutant lung cancer, regardless of the specific mutation upstream of MEK that drives activation of the MAPK pathway, and all while maintaining a well-tolerated safety profile in such models.

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

The consensus price target hints at a 223.5% upside potential for Immuneering Corporation (IMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade

CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will participate in two September investor conferences to share commentary around the Company's pipeline, platform, and business strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific Officer.

Immuneering Announces Participation in September Investor Conferences

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 15.38% and 65.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates

IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first patient in planned Phase 1/2a clinical trial expected in Q4 2022

News for Immuneering Corp Stock (IMRX)